The First 30 Minutes: Anaphylaxis After COVID Vaccination The First 30 Minutes: Anaphylaxis After COVID Vaccination
Most postvaccination symptoms are expected and not serious, although clinicians should be ready to manage the rare case of anaphylaxis.Medscape Internal Medicine (Source: Medscape Emergency Medicine Headlines)
Source: Medscape Emergency Medicine Headlines - January 27, 2021 Category: Emergency Medicine Tags: Internal Medicine Commentary Source Type: news
2.5 Anaphylaxis Cases Reported Per Million COVID-19 Moderna Vaccine Shots
MONDAY, Jan. 25, 2021 -- The rate of anaphylaxis is 2.5 cases per million Moderna COVID-19 vaccine doses administered as of Jan. 10, 2021, according to research published in the Jan. 22 issue of the U.S. Centers for Disease Control and Prevention... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 25, 2021 Category: Pharmaceuticals Source Type: news
Moderna Covid-19 Vaccine: Here Is The Risk Of Severe Allergic Reactions
A new CDC reported listed the rate of anaphylaxis after the Moderna Covid-19 mRNA as slightly lower than that of the Pfizer/BioNTech vaccine. But is this difference real? (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - January 23, 2021 Category: Pharmaceuticals Authors: Bruce Y. Lee, Senior Contributor Tags: Healthcare /healthcare Innovation /innovation Science /science business pharma Source Type: news
Covid US: 10 out of 4m who got Moderna vaccine suffered anaphylaxis
Just one person who went into anaphylactic shock - a life-threatening response in which a person's airways can become too narrow for them to breathe - had no history of allergies, CDC reports. (Source: the Mail online | Health)
Source: the Mail online | Health - January 23, 2021 Category: Consumer Health News Source Type: news
10 out of 4 million Americans to get Moderna's vaccine suffered anaphylaxis
Just one person who went into anaphylactic shock - a life-threatening response in which a person's airways can become too narrow for them to breathe - had no history of allergies, CDC reports. (Source: the Mail online | Health)
Source: the Mail online | Health - January 22, 2021 Category: Consumer Health News Source Type: news
Allergic reactions including anaphylaxis after receipt of 1st dose of Pfizer-BioNTech COVID-19 Vaccine
(JAMA Network) This JAMA Insights review provides clinical details of anaphylactic reactions reported to and verified by the Centers for Disease Control and Prevention in the first week of use of the Pfizer-BioNTech COVID-19 vaccine in the United States. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - January 21, 2021 Category: International Medicine & Public Health Source Type: news
How Safe Are Covid-19 Coronavirus Vaccines? Here ’s The Allergic Reaction Risk
A CDC report indicated that there were 21 cases of anaphylaxis (severe allergic reactions) out of 1,893,360 people who had received first doses of the Pfizer-BioNTech Covid-19 vaccine. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - January 16, 2021 Category: Pharmaceuticals Authors: Bruce Y. Lee, Senior Contributor Tags: Healthcare /healthcare Innovation /innovation Science /science business pharma Source Type: news
DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) Becomes the First FDA-Approved Treatment for Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
January 15, 2021 (HORSHAM, Pa.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj), a subcutaneous formulation of daratumumab, in combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd) for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis.[1] DARZALEX FASPRO® is the first and only FDA-approved treatment for patients with this blood cell disorder that is associated with the production of an abnormal protein, which leads to the deterior...
Source: Johnson and Johnson - January 16, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
COVID-19 vaccination programme, RCGP (updated 14th January 2021)
The latest updates on the COVID-19 vaccine, including:
COVID-19 Vaccination FAQs
SARS-CoV-2 Vaccination
#RCGPLive: COVID-19 vaccination in general practice
Managing anaphylaxis: guidance for GPs delivering the COVID-19 vaccine (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 15, 2021 Category: Consumer Health News Source Type: news
In lab study, nanoparticle shows promising results for treating severe allergies
For about 1 in 13 children in the U.S., usually harmless foodstuffs such as milk, eggs and peanuts can send the body ’s natural defenses into overdrive.Symptoms of food allergies can vary widely, but at worst, a systemwide allergic response can lead to anaphylaxis, a life-threatening condition characterized by a sudden drop in blood pressure and difficulty breathing.Although there are now some preventive measures for food-induced anaphylaxis, there are not yet any long-lasting solutions — treatments capable of locking the immune system into a state of tolerance, so that it doesn’t respond to allergens.Now, a UCLA res...
Source: UCLA Newsroom: Health Sciences - January 14, 2021 Category: Universities & Medical Training Source Type: news
Update on COVID-19 pandemic, BMJ Best Practice (updated 8th January 2021)
Over 88 million cases have been reported globally, with over 49 million cases recovered so far, and approximately 1.9 million deaths according to data compiled by the Center for Systems Science and Engineering at Johns Hopkins University.
What ' s new at this update: Epidemiology: updated data on children and pregnant women; updated risk factors (residence in a long-term care facility; cardiovascular diseases; diabetes; chronic respiratory diseases). Aetiology: new section on SARS-CoV-2 variants; updated data on secondary attack rates. Investigations: WHO recommends PCR test results are consider...
Source: Current Awareness Service for Health (CASH) - January 11, 2021 Category: Consumer Health News Source Type: news
Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine United States, December 14-23, 2020, Morbidity and Mortality Weekly Report
During 14 –23 Dec 2020, there were 21 reports of anaphylaxis after administration of 1,893,360 first doses of the Pfizer-BioNTech COVID-19 vaccine (11.1 cases per million doses) made to the Vaccine Adverse Event Reporting System; 71% occurred within 15 minutes of vaccination. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 11, 2021 Category: Consumer Health News Source Type: news
What Are the Signs of Anaphylaxis
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - January 11, 2021 Category: General Medicine Source Type: news
What Are the Two Signs of Anaphylaxis?
Title: What Are the Two Signs of Anaphylaxis?Category: Diseases and ConditionsCreated: 1/11/2021 12:00:00 AMLast Editorial Review: 1/11/2021 12:00:00 AM (Source: MedicineNet Allergies General)
Source: MedicineNet Allergies General - January 11, 2021 Category: Allergy & Immunology Source Type: news
11.1 Anaphylaxis Cases/Million Doses of Pfizer-BioNTech COVID-19 Vaccine Reported
THURSDAY, Jan. 7, 2021 -- As of Dec. 23, 2020, researchers determined there were 21 cases of anaphylaxis (11.1 per million doses administered) after receipt of the first dose of the Pfizer-BioNTech COVID-19 vaccine in the United States, according to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 7, 2021 Category: Pharmaceuticals Source Type: news
